September 2026 Research Update

This month included one large real-world study that compared Fabry patients who did versus did not receive SGLT2 inhibitors (a class of diabetes and kidney medicines) and found fewer serious heart-related outcomes in the group who used them. The pattern was consistent at both 2 and 5 years, including a lower risk of death in the SGLT2 inhibitor group. Because the study was observational, it cannot prove the medicine caused the difference, but it strengthens the signal that this drug class is worth testing in prospective studies in Fabry disease. [1]

After matching patients to make the two groups more comparable, SGLT2 inhibitor exposure was linked to a lower risk of a combined outcome made up of death, heart attack, and acute heart failure. The same analysis also reported a lower risk of heart attack by 5 years. Details such as why patients were prescribed SGLT2 inhibitors and how Fabry-specific treatments were used alongside them were not provided in the summary, which matters when interpreting real-world comparisons. [1]

For patients and caregivers, this adds an encouraging but still indirect piece of evidence: in routine care data, people with Fabry disease who were on SGLT2 inhibitors had fewer major heart-related events and fewer deaths over follow-up. This may matter now mainly as context for ongoing research, because observational studies can be influenced by who gets prescribed a drug and who does not. What remains uncertain is whether the same benefit would be seen if tested in a prospective study designed to answer cause-and-effect, and which Fabry subgroups (kidney function, heart involvement, other treatments) might benefit most. [1]

This month made the picture of Fabry-related heart disease a bit more specific: different parts of the heart can change on different timelines, and tests that combine electrical signals (ECG) with heart structure (imaging) may help distinguish Fabry from look-alike conditions. Across studies, the message was not that a single number tracks everything, but that looking at several domains together can better describe where a person is on a heart disease pathway. These results are meant to improve understanding and classification, and some of the approaches are still exploratory. [2] [3]

In one multicenter follow-up study of 38 Fabry patients, electrical heart measurements worsened over time more clearly than some imaging measures, with QRS duration increasing while heart muscle mass did not show a significant change and heart strain changes were not clearly significant. The researchers grouped patients into four "remodeling" patterns that mixed electrical and mechanical changes, and the distribution of these patterns differed between people who had received enzyme replacement therapy and those who had not. This supports the idea that Fabry heart involvement is not a single straight-line process, although the small, retrospective dataset means the groups may differ in ways not captured in the summary. [2]

A separate large multicenter analysis of adults with thickened heart walls compared cardiac amyloidosis, hypertrophic cardiomyopathy, and Anderson-Fabry disease using combined ECG and echocardiogram indices. All of the tested indices separated amyloidosis from the other conditions, and one index (total QRS divided by maximum wall thickness) was reported as the best at distinguishing among all three groups. For patients, this mainly matters because these conditions can look similar on standard imaging, but may have different causes and care pathways, so better separation at the testing stage can reduce diagnostic uncertainty. [3]

Another retrospective study looked at cardiac MRI image quality using gadopiclenol contrast at two dose levels in Anderson-Fabry disease. Both doses produced diagnostic-quality late enhancement images, with slightly higher contrast at the higher dose and no difference in native (pre-contrast) heart T1 values between groups. This is technical work focused on how to obtain usable images, and it needs prospective confirmation before it can be considered a standard approach. [4]

For patients, these studies add practical understanding rather than a new treatment result: Fabry-related heart disease may show changes in electrical activity, pumping mechanics, and wall thickness that do not move together. This may matter when someone is being followed over time or when doctors are trying to distinguish Fabry from other causes of a thickened heart, especially amyloidosis and hypertrophic cardiomyopathy. What remains uncertain is how well the proposed "remodeling" patterns predict future symptoms or outcomes, and whether changing imaging methods (like contrast dose) affects clinical decisions beyond improving image quality. [2] [3] [4]

This month added evidence that who gets tested, and how they are tested, strongly shapes what "Fabry disease" looks like in real-life cohorts. Studies described that broad gene panels are identifying more non-classical variants where heart disease is the main feature, while broad screening in an unrelated referral group (suspected demyelinating disease) mostly found benign or non-diagnostic gene changes. Taken together, the results make Fabry diagnosis look less like a single pathway and more like several entry points depending on symptoms and testing strategies. [5] [6]

In a Dutch national cohort analysis, adding the GLA gene to broad sequencing panels increased the proportion of non-classical, milder variants in newly identified index patients, and cardiomyopathy became the most common reason people were tested in recent years. This helps explain why more people are being diagnosed with Fabry based mainly on heart findings, sometimes with fewer of the classic early symptoms. The study also highlighted the need for variant-specific counseling and follow-up, because different variants can be linked to different levels and types of risk. [5]

In a separate clinic-based screening study of 584 people evaluated for possible demyelinating disease, reportable GLA findings were uncommon and were usually a benign pseudodeficiency allele rather than a pathogenic Fabry variant. Pathogenic variants were rare, and none of the people with a pathogenic Fabry variant met criteria for multiple sclerosis in the final neurologic assessment described in the summary. This suggests that testing everyone in a demyelinating clinic mainly finds variants that do not explain the neurologic diagnosis, although the study also noted some unadjusted, imprecise MRI associations that need cautious interpretation. [6]

For patients and caregivers, this mainly clarifies why Fabry can be diagnosed in very different ways today compared with a decade ago. Broader genetic panels can pick up milder or heart-first forms, which may increase the number of people learning they have a GLA variant when heart thickening is the main issue. At the same time, blanket screening in some settings may mostly find benign or unclear variants, which can create uncertainty rather than clear answers. What remains uncertain is how best to interpret some of these milder or non-classical findings over time, and which follow-up strategies are most useful for different variants. [5] [6]

This month included exploratory work trying to connect Fabry biology to symptoms and organ damage, especially nerve pain and kidney involvement. The studies do not change care now, but they sharpen what researchers are measuring: subtle nerve changes that may not be obvious on routine exams, and specific lipid pathways in pain-sensing nerves in animals. In parallel, new lab-grown kidney cell systems were described that can be engineered to show Fabry-like defects, which may accelerate testing of ideas in a human-relevant model. [7] [8] [9]

In a small cross-sectional study comparing 13 Fabry patients with 13 controls, motor unit measurements were mostly preserved, but one lower-leg muscle showed differences suggesting subtle distal motor involvement. The study also reported that higher lyso-Gb3 levels correlated with one motor unit measure, and that worse neuropathy symptom scores tracked with one muscle signal measure. For patients, this mainly supports the idea that Fabry neuropathy may include more than pain fibers alone in some people, even when weakness is not prominent. [7]

In Fabry mice, researchers linked pain hypersensitivity to buildup of a specific membrane lipid (phosphatidylglycerol) in pain-sensing nerve clusters, along with signs of mitochondrial disruption. Reducing a lipid-making enzyme (PGS1) or restoring sPLA2 activity reduced the lipid buildup and reduced pain behaviors in the animals. This is laboratory research and does not show that the same pathway is the main driver of pain in people, but it gives specific targets to study in human samples in the future. [8]

A separate preclinical study created more mature, lab-grown human proximal tubule cells from kidney organoids and used gene editing to disrupt alpha-galactosidase A, producing Fabry-like functional changes. The system also performed better than older cell models for predicting kidney toxicity on a chip, and transplanted cells could re-form tubule-like structures in mouse kidneys. For Fabry research, the value is that a human-based kidney model may help test hypotheses and potential therapies earlier, before moving to clinical studies. [9]

One exploratory human study looked at DNA methylation patterns and biological aging measures in 32 Fabry patients and did not find robust genome-wide methylation differences after correcting for multiple testing. The group with pathogenic GLA variants did show a higher DunedinPACE score, a measure intended to reflect the pace of biological aging, but the authors noted that this requires replication in larger cohorts. For patients, this is an early signal that can guide future research rather than a test used in routine Fabry care. [10]

For patients, these studies mostly add to understanding of what might be happening under the surface in nerves and kidneys, and what scientists are trying to measure next. The human nerve study suggests there may be subtle motor nerve involvement in some people with Fabry disease, while the mouse study points to a specific lipid pathway that could help explain pain biology if confirmed in humans. The kidney organoid work matters later rather than now, because it provides a new lab platform that can mimic Fabry-related proximal tubule problems and may speed up research testing. What remains uncertain is how directly these early signals translate into symptoms, progression, or treatment response in real-world Fabry disease. [7] [8] [9] [10]

The case reports this month reinforced how varied Fabry presentations can be, especially when the heart is the main organ involved or when symptoms start with pain. They also showed common real-life diagnostic challenges: distinguishing Fabry-related vessel disease from early atherosclerosis, and interpreting genetic variants that do not yet have definitive proof of pathogenicity. Because these are individual cases, they cannot predict what will happen for most people, but they illustrate situations that can come up in practice. [11] [12] [13] [14]

One report described a 39-year-old man with Fabry disease who developed unstable angina from a narrowing in a major coronary artery, where detailed vessel imaging suggested an unusual pattern without typical plaque appearance. After drug-coated balloon angioplasty, blood-flow measurements improved and he had no return of angina over 2 years, but the authors noted that imaging could not definitively separate Fabry vasculopathy from premature atherosclerosis. This matters because chest pain in Fabry can have more than one possible cause, and imaging sometimes cannot give a single clear explanation. [11]

Two other reports centered on heart thickening and diagnostic uncertainty around Fabry. One family report identified a novel GLA variant classified as a variant of uncertain significance, alongside low enzyme activity and elevated lyso-Gb3 in the proband and supportive inheritance patterns, but without functional proof that the variant causes disease. Another report described autopsy findings consistent with, but not diagnostic for, a non-classical cardiac Fabry variant because electron microscopy, enzyme testing, and genetic testing were not available. [12] [13]

A separate family report described a teenage girl whose first major symptom was long-standing bilateral foot pain, with Fabry disease confirmed by a disease-causing GLA change, and her father had a similar history that progressed to dialysis. The report noted that the girl had normal alpha-galactosidase A enzyme activity despite carrying the variant, which can occur in females and can complicate recognition if enzyme testing is used alone. For families, this highlights how neuropathic pain can be an early sign and why diagnosis may require more than one type of test. [14]

For patients and caregivers, these reports are most useful as real examples of the range of Fabry presentations and the limits of certainty in some diagnostic pathways. They show that Fabry-related heart problems can involve chest pain and coronary narrowing, and that some situations leave uncertainty when specialized testing is missing or when a genetic change is still classified as uncertain. They also show that females may have normal enzyme activity even when a disease-causing variant is present, which can delay recognition if testing is incomplete. What remains uncertain in case reports is how common each pattern is and which findings reliably apply to other patients. [11] [12] [13] [14]

One small retrospective series this month provided a snapshot of how Fabry disease looked in a single hospital cohort, with kidney and heart involvement being common. The report also described real-world enzyme replacement therapy use and noted that both treatment-related reactions and serious cardiac outcomes can occur during follow-up in a small group. Because the series included only 9 patients, it is best read as a descriptive window into variability rather than a measure of typical risk. [15]

Across the 9 patients with confirmed Fabry disease, renal impairment was reported in 7 and cardiac involvement in 8, with autonomic symptoms in 6. Treatment included agalsidase alpha in 1 patient and agalsidase beta in 8 patients, and the authors reported one infusion-associated reaction after 12 infusions. During follow-up, one patient died due to cardiac complications, highlighting that advanced heart disease can be part of the Fabry course in some individuals. [15]

For patients, this series mainly reinforces two points already familiar to many families: Fabry disease often involves both kidneys and the heart, and people can have a mix of organ and nervous system symptoms. It also provides a reminder that infusion reactions can happen with enzyme replacement therapy and that serious heart complications were observed in this small cohort, though the study is too small to estimate how often these events happen overall. What remains uncertain from this report is how representative this single-center group is of Fabry patients in other settings and how differences in variants, timing of diagnosis, and other health conditions shaped outcomes. [15]